Drug Trial Radar · NCT05508100
Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors
Last checked: Nov 19, 2026Latest source record: May 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
38
Actual
Start
Sep 9, 2022
Primary completion
Apr 30, 2024
Study completion Apr 30, 2024
Sponsor
- Lead sponsor
- Immune-Onc TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Aug 19, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1 study to evaluate the safety, tolerability, PK, and preliminary efficacy of IO-108 monotherapy and in combination with anti-PD-1 monoclonal antibody pembrolizumab or tislelizumab in adult patients with advanced solid tumors. The study will be conducted in 3 parts, including Part A IO-108 monotherapy dose confirmation; Part B IO-108 + anti-PD-1 dose confirmation, and Part C dose expansion.
Conditions
- Advanced Solid Tumor
Interventions
IO-108Biological
IO-108, intravenously, on Day 1 of each 21-day cycle.
IO-108 + pembrolizumabBiological
IO-108, intravenously, on Day 1 of each 21-day cycle. Pembrolizumab will be administered intravenously on Day 1 of each 21-day cycle.
IO-108 + tislelizumabBiological
IO-108, intravenously, on Day 1 of each 21-day cycle. Tislelizumab will be administered intravenously on Day 1 of each 21-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs) in patients treated with IO-108Time frame: through study completion, an average of 2 years
- Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs) in patients treated with IO-108 in combination with pembrolizumab or tislelizumabTime frame: through study completion, an average of 2 years
- Preliminary anti-tumor activity of IO-108 in combination with pembrolizumab or tislelizumabTime frame: through study completion, an average of 2 years
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Fujian Medical University
Fujian, Fuzhou, China
1st affiliated Hospital of Hainan Medical University
Haikou, Hainan, China
4th Hospitla of Hebei Medical University
Shijiazhuang, Hebei, China
Harbin Cancer Hospital
Harbin, Heilongjiang, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Tongji Hospital
Wuhan, Hubei, China
Hunan Cancer Hospital
Changsha, Hunan, China
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Liaoning Cancer Hospital
Shenyang, Liaoning, China
Shandong Cancer Hospital
Jinan, Shandong, China
Lin Yi Cancer Hospital
Linyi, Shandong, China
Shanghai Dong Fang Hospital
Shanghai, Shanghai Municipality, China
1st Affiliated Hospital of Xi'an Jiaotong University
Xian, Shanxi, China
Sir RUN RUN SHAW HOSPITAL
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.